Biogen enters strategic alliance to develop new Parkinson’s disease treatments

Biogen has formed a strategic alliance with the Parkinson’s Institute and Clinical Center to improve understanding of the underlying biology of Parkinson’s disease (PD) and discover new tools and programs to accelerate research and development of new PD treatments. The deal will combine the institute’s clinical expertise and data with Biogen’s focus on neurodegenerative disease

Continue Reading

MRC, GSK and UK Uni’s Collab for Inflammatory Diseases Drug Development

GlaxoSmithKline (GSK) and the UK’s Medical Research Council (MRC) will be collaborating in an open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will bring together researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL, with GSK scientists

Continue Reading

Doctors and Nurses Told to Admit Mistakes

According to new guidelines, face-to-face explanations and apologies will need to be given to patients or close ones when things regarding their treatment and wellbeing go wrong. The guidance follows Sir Robert Francis’ call for a more open and transparent culture within healthcare in his report following the failures in patient care at Mid Staffordshire

Continue Reading

NHS: £190m set aside for Hepatitis C

The budget for HCV therapies will be increased from last year’s £40 million to £190 million says NHSE (NHS England). This will provide stop-gap access to drugs such as AbbVie’s on Viekirax and Exviera to around 3,500 patients with cirrhosis. NHSE’s Clinical Priorities Advisory Group (CPAG) is recommending that Viekirax/Exviera should be offered to all

Continue Reading

Teva $40 Billion Offer to Acquire Mylan

Following weeks of speculation, Teva yesterday made a $40-billion-bid for Mylan NV. Teva has offered $82 per Mylan share in a 50/50 cash/stock transaction valued at just over $40 billion. However, the reaction so far to the news suggests that Teva would need to improve on their bid for it to be accepted.  S&P Capital

Continue Reading

Johnson & Johnson Exceed Q1 Estimates

Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar.  The negative currency effect is expected to continue to

Continue Reading

Takeda Signs Oncology Biotech Deal

Takeda has announced that they have signed a deal with ImmunoGen for two anticancer targets. Takeda signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals. The agreement, which grants Takeda exclusive rights to use ImmunoGen’s ADC technology for anticancer therapeutics, could be worth up to $230m. Specifically, the Japanese pharmaceutical company has licensed exclusive

Continue Reading